前往化源商城

595-91-5 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Nuclear receptor subfamily 4 group A member 3
External ID: CHEMBL5392242
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2023
Volume: 66
Issue: 22
First Page: 15362
Last Page: 15369
DOI: 10.1021/acs.jmedchem.3c01467

Target ChEMBL ID: CHEMBL1961792
ChEMBL Target Name: Nuclear receptor subfamily 4 group A member 3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
100IC50>100000nM
100IC50>100000nM
100IC50>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Nuclear receptor subfamily 4 group A member 2
External ID: CHEMBL5392238
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2023
Volume: 66
Issue: 22
First Page: 15362
Last Page: 15369
DOI: 10.1021/acs.jmedchem.3c01467

Target ChEMBL ID: CHEMBL5002
ChEMBL Target Name: Nuclear receptor subfamily 4 group A member 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
100IC50>100000nM
37IC50=37000nM
100IC50>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:N/A
External ID: TargetID_659_CEMA
Protocol: Black, standard capacity streptavidin-coated 384-well plates (Pierce 15407) were first washed with 50 L of phosphate buffer (100 mM, pH 7.0; PB7) three times using a Biotek 405 ELX plate washer. Subsequently, 5 L of biotinylated pre-miRNA substrate (500 nM final) was dispensed into the plate using a Multidrop Combi Reagent Dispenser (Thermo Scientific). Plates were then centrifuged for 1 min at 1,000 RPM (223 g), sealed with plate tape, and incubated overnight at 4 C. The following morning, plates were washed three times with 50 L of PB7, followed by the addition of 5 L of Dicer digest buffer (20 mM Tris, 12 mM NaCl, 2.5 mM MgCl2, 1 mM fresh DTT, and 4.5% DMSO) and centrifugation. Compounds (50 nL of 5 mM DMSO stock, 25 M final) were then added into the sample wells using a Sciclone (Caliper) liquid handler with V&P pintool; the same volume of DMSO was added to the control wells. The plates were incubated at 25 C for 15 min before addition of 5 L of digest buffer containing 217 g/nL Dicer (108 g/mL Dicer, 5% glycerol and 0.01% Triton X-100 final, excess with respect to pre-miRNA). For the positive control wells, digest buffer without Dicer was added. The plates were centrifuged again and resealed before being placed in a 37 C incubator for 5 h. After Dicer cleavage, plates were washed three times with 50 L of PB7. mTet-HRP in PB7 (10 L, 750 nM final) was then dispensed into each well. The plates were subsequently centrifuged, sealed, and incubated at 25 C for 2 h. Plates were then washed three times with 50 L of wash buffer (2 mM imidazole, 260 mM NaCl, 0.5 mM EDTA, 0.1% Tween-20, pH 7.0), followed by washing three additional times with 50 L of PB7. Finally, SuperSignal West Pico (25 L; Pierce) was added, the plates were incubated at 25 C for 5 min, and chemiluminescence signal was detected using a PHERAstar plate reader using LUM plus module (BMG Labtech).
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.

For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.
Z_SCORE
2.91
-0.56
0.61
2.15
0.54
-0.32
1.12
-0.07
0.61
1.55
-0.77
-0.76
-2.08
0.67
-0.35
0.17
-1.42
-0.64
-5.35
1.42
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: MCF7_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, MCF7 is panel number 5, cell number 1. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
2106OS49SM1.0E-551Breast CancerMCF7BRE88.231101
2106OS49SM1.0E-551Breast CancerMCF7BRE87.1119101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.4371101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.7113101
2106OS49SM1.0E-551Breast CancerMCF7BRE97.2463101
2106OS49SM1.0E-551Breast CancerMCF7BRE90.0129101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.7031101
2106OS49SM1.0E-551Breast CancerMCF7BRE30.8539101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.2896101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.8526101
2106OS49SM1.0E-551Breast CancerMCF7BRE83.1036101
2106OS49SM1.0E-551Breast CancerMCF7BRE84.2194101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.3237101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.6034101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.6643101
2106OS52SM1.0E-551Breast CancerMCF7BRE91.2503101
2106OS52SM1.0E-551Breast CancerMCF7BRE94.8714101
2106OS52SM1.0E-551Breast CancerMCF7BRE93.7372101
2106OS52SM1.0E-551Breast CancerMCF7BRE112.6132101
2106OS52SM1.0E-551Breast CancerMCF7BRE73.375101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Nuclear receptor subfamily 4immunitygroup A member 1
External ID: CHEMBL5392235
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2023
Volume: 66
Issue: 22
First Page: 15362
Last Page: 15369
DOI: 10.1021/acs.jmedchem.3c01467

Target ChEMBL ID: CHEMBL1293229
ChEMBL Target Name: Nuclear receptor subfamily 4 group A member 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
100IC50>100000nM
9IC50=9000nM
100IC50>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: IGROV1_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, IGROV1 is panel number 6, cell number 10. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
0809OS51SM1.0E-5610Ovarian CancerIGROV1OVA89.6274101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA94.0185101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA77.1805101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA76.1686101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA82.5618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA88.7561101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA83.5845101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA92.7497101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA70.9555101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA58.7306101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.6041101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA90.3839101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA110.2345101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA97.6538101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA93.7697101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA56.4618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA80.8893101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA79.078101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA-20.3008101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.0949101